Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
In recent events, ADI Regional Director for Asia-Pacific, DY Suharya, was invited to contribute to key summits, events and meetings, with a key focus on improving dementia care, innovating dementia technology and advising on advocacy across the Asia-Pacific region and beyond.
ADI is sharing a round-up of our recent action in Europe, on advocacy and research, with ADI Board Vice Chair, Meera Pattabiraman, and ADI Director of Research and Publications, Wendy Weidner. Both taking part in vital dialogues in June 2024.
In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.
In May 2024, the ADI delegation returned to Geneva, Switzerland, for the World Health Organization’s 77th annual World Health Assembly to launch ’From Plan To Impact VII: Dementia at a crossroads’. Read ADI's highlights from the event.
In April 2024, the world's longest-running global conference on Alzheimer's disease and dementia came to Kraków, Poland, to provide the latest insights, innovations and inspirations on dementia over three days, six plenary sessions, 29 parallel sessions and eight symposiums to over 1000 delegates representing over 100 countries.
ADI CEO, Paola Barbarino took to the stage at the ADI 2024 Conference in Krákow, Poland, to highlight the global and national policy landscape on dementia, providing her perspective on the achievements of ADI in the past four decades and hopes for the future.
This year, 2024 marks the 40th year of Alzheimer's Disease International and our work to secure a future that includes greater awareness of the condition, increased access to care, post-diagnostic support,and emerging treatments as well as a achieving a world without stigma. ADI invites our global community to celebrate with us on this momentous occasion with thanks to all who have been with us on this journey over four decades.
The EMA regulates the availability of medicines across all 27 European Union Member States as well as Iceland, Norway, and Liechtenstein.